论文部分内容阅读
目的探讨围手术期应用曲美他嗪对经皮冠状动脉介入术(PCI)患者术中缺血事件及心肌功能的影响。方法 780例PCI手术患者,随机分为对照组(390例)与观察组(390例)。对照组围手术期给予常规治疗,观察组同时使用曲美他嗪。记录两组患者术中出现缺血性ST-T改变的发生率,检测患者术前术后心肌肌钙蛋白I(c Tn I)、肌酸激酶同工酶(CK-MB)及超敏C反应蛋白(hs-CRP)水平。结果观察组患者术后c Tn I(0.32±0.28)ng/ml、CK-MB(45.17±8.96)U/L及hs-CRP(5.28±1.56)mg/L等心肌损伤标志物水平均低于对照组(P<0.05);观察组患者术中缺血事件发生率(12.8%)低于对照组(33.3%),两组比较差异有统计学意义(P<0.05)。结论 PCI围手术期应用曲美他嗪能有效预防缺血事件发生,对保护心肌功能有积极影响。
Objective To investigate the effect of perioperative trimetazidine on ischemic events and myocardial function in patients undergoing percutaneous coronary intervention (PCI). Methods A total of 780 PCI patients were randomly divided into control group (390 cases) and observation group (390 cases). Patients in the control group were treated by perioperative period. Trimetazidine was used in the observation group. The incidence of ischemic ST-T changes in the two groups was recorded and the cardiac troponin I (cTn I), creatine kinase MB (CK-MB) and hypersensitivity C Reactive protein (hs-CRP) levels. Results The myocardial injury markers such as cTn I (0.32 ± 0.28) ng / ml, CK-MB (45.17 ± 8.96) U / L and hs-CRP (P <0.05). The incidence of ischemic events in the observation group (12.8%) was lower than that in the control group (33.3%). There was significant difference between the two groups (P <0.05). Conclusion Perioperative trimetazidine can effectively prevent ischemic events and has a positive effect on the protection of myocardial function.